Sarp K Keskin1, Pavlos Msaouel2, Kenneth R Hess3, Kai-Jie Yu4, Surena F Matin1, Kanishka Sircar5, Pheroze Tamboli5, Eric Jonasch2, Christopher G Wood1, Jose A Karam1, Nizar M Tannir6. 1. Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2. Department of Genitourinary Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas. 3. Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, Texas. 4. Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan. 5. Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas. 6. Department of Genitourinary Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: ntannir@mdanderson.org.
Abstract
PURPOSE: We studied overall survival and prognostic factors in patients with sarcomatoid renal cell carcinoma treated with nephrectomy and systemic therapy in the cytokine and targeted therapy eras. MATERIALS AND METHODS: This is a retrospective study of patients with sarcomatoid renal cell carcinoma who underwent nephrectomy and received systemic therapy at our center in the cytokine era (1987 to 2005) or the targeted therapy era (2006 to 2015). Multivariate regression models were used to determine the association of covariables with survival. RESULTS: Of the 199 patients with sarcomatoid renal cell carcinoma 167 (83.9%) died (median overall survival 16.5 months, 95% CI 15.2-20.9). Survival of patients with clear cell histology was significantly longer vs those with nonclear cell histology (p = 0.034). Patients with synchronous metastatic disease had significantly shorter survival than patients with metachronous metastatic disease (median 12.1 vs 23.3 months, p = 0.0064). Biopsy of the primary tumor or a metastatic site could detect the presence of sarcomatoid features in only 7.5% of cases. Although a significant improvement in survival rate was observed in the first year in patients treated in the targeted therapy era (p = 0.011), this effect was attenuated at year 2, disappeared at years 3 to 5 after diagnosis and was not evident in patients with poor risk features. CONCLUSIONS: Patients with sarcomatoid renal cell carcinoma still have poor prognosis with no clear long-term benefit of targeted therapy. This underscores the need to develop more effective systemic therapies for these patients.
PURPOSE: We studied overall survival and prognostic factors in patients with sarcomatoid renal cell carcinoma treated with nephrectomy and systemic therapy in the cytokine and targeted therapy eras. MATERIALS AND METHODS: This is a retrospective study of patients with sarcomatoid renal cell carcinoma who underwent nephrectomy and received systemic therapy at our center in the cytokine era (1987 to 2005) or the targeted therapy era (2006 to 2015). Multivariate regression models were used to determine the association of covariables with survival. RESULTS: Of the 199 patients with sarcomatoid renal cell carcinoma 167 (83.9%) died (median overall survival 16.5 months, 95% CI 15.2-20.9). Survival of patients with clear cell histology was significantly longer vs those with nonclear cell histology (p = 0.034). Patients with synchronous metastatic disease had significantly shorter survival than patients with metachronous metastatic disease (median 12.1 vs 23.3 months, p = 0.0064). Biopsy of the primary tumor or a metastatic site could detect the presence of sarcomatoid features in only 7.5% of cases. Although a significant improvement in survival rate was observed in the first year in patients treated in the targeted therapy era (p = 0.011), this effect was attenuated at year 2, disappeared at years 3 to 5 after diagnosis and was not evident in patients with poor risk features. CONCLUSIONS:Patients with sarcomatoid renal cell carcinoma still have poor prognosis with no clear long-term benefit of targeted therapy. This underscores the need to develop more effective systemic therapies for these patients.
Authors: E Jason Abel; Jennifer E Heckman; Louis Hinshaw; Sara Best; Meghan Lubner; David F Jarrard; Tracy M Downs; Stephen Y Nakada; Fred T Lee; Wei Huang; Timothy Ziemlewicz Journal: J Urol Date: 2015-03-30 Impact factor: 7.450
Authors: Brian Shuch; Jonathan Said; Jeff C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Fairooz F Kabbinaavar; Allan J Pantuck; Arie S Belldegrun Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Sumanta K Pal; Jeremy O Jones; Courtney Carmichael; Junmi Saikia; Joanne Hsu; Xueli Liu; Robert A Figlin; Przemyslaw Twardowski; Clayton Lau Journal: Urol Oncol Date: 2012-05-17 Impact factor: 3.498
Authors: Badar M Mian; Nishin Bhadkamkar; Joel W Slaton; Peter W T Pisters; Danai Daliani; David A Swanson; Louis L Pisters Journal: J Urol Date: 2002-01 Impact factor: 7.450
Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226
Authors: Mitsuru Takeuchi; Adam T Froemming; Akira Kawashima; Prabin Thapa; Rickey E Carter; John C Cheville; R Houston Thompson; Naoki Takahashi Journal: Abdom Radiol (NY) Date: 2022-04-05
Authors: Dylan J Martini; Meredith R Kline; Yuan Liu; Julie M Shabto; Bradley C Carthon; Greta Anne Russler; Lauren Yantorni; Emilie Elise Hitron; Sarah Caulfield; Jamie M Goldman; Wayne B Harris; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen Journal: Cancer Treat Res Commun Date: 2021-05-09